We’re excited to announce that 𝗙𝗿𝗼𝗻𝘁𝗶𝗲𝗻𝘁 𝟰𝟬𝟬𝗺𝗴 (𝗜𝗡𝗡: 𝗣𝗮𝘇𝗼𝗽𝗮𝗻𝗶𝗯) is now available in Bosnia and Herzegovina, following its launch at the end of March. This marks one of the first generic launches of Pazopanib in the Western Balkans - a step forward in expanding access to oncology treatments in the region. Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma.

In our second Leading the Way interview, Snezana Stojilkovic, Zdravlje’s Quality Director, shares insights from her 30-year journey—from researcher to leading quality operations. She discusses the challenges of maintaining top-tier standards in a CDMO, the power of cross-team collaboration, and how our commitment to excellence drives success.

Zdravlje AD Leskovac and Sava Health d.o.o. have entered into a strategic partnership for the distribution and promotion of a segment of Zdravlje’s portfolio in the Serbian market.

Zdravlje/Frontier Biopharma has secured a new Marketing Authorization for Dimethyl Fumarate Frontier (120 mg and 240 mg hard gastro-resistant capsules) in Romania, building on previous approvals in Croatia, Bulgaria, and Slovenia. This achievement further strengthens the company’s presence in the European market.

Zdravlje recently completed a comprehensive six-day inspection by the European Medicines Authority from September 5-10, concluding successfully with zero critical observations. Recognized with the prestigious EU GMP certification since 2009, our facility continues to uphold full compliance and excellence in quality, innovation, and trust.

As part of our new series, Leading The Way, we are proud to bring you exclusive insights from the leaders who are shaping the future of Zdravlje. In each interview, we’ll dive into their unique perspectives, key experiences, and the strategies they employ to drive our company forward. Through these conversations, we aim to highlight the vision, innovation, and leadership that have defined Zdravlje for decades. In this first interview, we sit down with Dusan Cvetanovic, Senior Site Director, to explore his journey and his thoughts on the future of our industry.

We are proud to announce that Zdravlje has been 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗯𝘆 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀, an independent 𝗴𝗹𝗼𝗯𝗮𝗹 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝗿 𝗼𝗳 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗿𝗮𝘁𝗶𝗻𝗴𝘀, placing us in the 𝘁𝗼𝗽 𝟯𝟱% 𝗼𝗳 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 assessed globally for sustainability! This recognition is especially significant as it follows our first audit in the ESG field. EcoVadis, a globally respected sustainability ratings provider, evaluates companies based on 21 sustainability criteria, including environmental impact, labor and human rights, ethics, and sustainable procurement.

We are excited to announce Serbia's commencement of constructing the BIO4 campus in Belgrade! This campus is set to become a central hub for innovation, research and collaboration, uniting brilliant minds with cutting-edge technologies. As Zdravlje, we are honoured to play a role in this ground-breaking project, poised to redefine the biotechnology landscape in Europe. Our commitment is to pioneer the development of novel biologics for the prevention and treatment of life-threatening diseases.

The successful and long-term business of Zdravlje was also recognized by the Chamber of Commerce of Serbia (PKS). At the premises of the Regional Chamber of Commerce (RPK) in Leskovac, during the ceremonial session of the Parliament of Businessmen, Zdravlje was presented with the JUBILEE AWARD OF THE CHAMBER OF COMMERCE OF SERBIA for 70 years of successful business.

Zdravlje Leskovac ceremoniously marked a significant milestone - seven decades of dedication to innovation, trust, and quality. The celebration, held on Friday, November 24, brought together more than 350 guests, including our business partners, collaborators, and representatives of institutions who, along with our employees, reminisced about the extensive history of Zdravlje.